- RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
This study is for people with a certain type of lung cancer (NSCLC) that has a specific gene change (KRAS G12C). It's testing a new drug, calderasib, alongside a common immunotherapy, durvalumab, to see if this combination helps more after standard chemotherapy and radiation.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This study is testing a new drug combination for a specific type of lung cancer that has been removed by surgery. It compares two treatments: a new drug (Calderasib) with an existing one (MK-3475A), against the existing drug plus a dummy treatment, to see if it helps stop the cancer from coming back.
For: Non-small Cell Lung CancerArgentina · Australia · Brazil - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This study is testing a new drug called Calderasib, alone or with other treatments, for advanced cancers with a specific gene change (KRAS G12C). It's looking at how safe and effective these treatments are.
For: Advanced Solid TumorsUnited States · Argentina · Australia - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
For: Neoplasm MalignantUnited States · Australia · Canada